Curis to Present at Upcoming Healthcare Conferences
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will participate in two upcoming conferences: the B. Riley Virtual Oncology Conference on January 27, 2022, at 1:30 p.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be accessible on their website, and archived replays will be available for 90 days afterward.
Curis focuses on innovative cancer therapeutics, including trials on the IRAK4 inhibitor CA-4948.
- None.
- None.
LEXINGTON, Mass., Jan. 20, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer, will participate in the following upcoming conferences:
- B. Riley Virtual Oncology Conference, Thursday, January 27, 2022 at 1:30 p.m. ET
- SVB Leerink 11th Annual Global Healthcare Conference, Friday, February 18, 2022 at 11:20 a.m. ET
Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. Archived replays of the webcasts will be available on the Curis website for 90 days following the event.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-301464302.html
SOURCE Curis, Inc.
FAQ
When will Curis present at the B. Riley Virtual Oncology Conference?
What is the date for the SVB Leerink Global Healthcare Conference presentation by Curis?
Where can I watch the live webcasts of Curis's conference presentations?
What is the focus of Curis, Inc. in the biotechnology field?
What trials is Curis conducting related to CA-4948?
